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Abstract
In the kidney vitamin D is converted to its active form. Since vitamin D exerts its activity through binding to the nuclear
vitamin D receptor (VDR), most genetic studies have primarily focused on variation within this gene. Therefore, analysis of
genetic variation in VDR and other vitamin D pathway genes may provide insight into the role of vitamin D in renal cell
carcinoma (RCC) etiology. RCC cases (N=777) and controls (N=1,035) were genotyped to investigate the relationship
between RCC risk and variation in eight target genes. Minimum-p-value permutation (Min-P) tests were used to identify
genes associated with risk. A three single nucleotide polymorphism (SNP) sliding window was used to identify chromosomal
regions with a False Discovery Rate of ,10%, where subsequently, haplotype relative risks were computed in Haplostats.
Min-P values showed that VDR (p-value=0.02) and retinoid-X-receptor-alpha (RXRA) (p-value=0.10) were associated with
RCC risk. Within VDR, three haplotypes across two chromosomal regions of interest were identified. The first region, located
within intron 2, contained two haplotypes that increased RCC risk by approximately 25%. The second region included a
haplotype (rs2239179, rs12717991) across intron 4 that increased risk among participants with the TC (OR=1.31, 95%
CI=1.09–1.57) haplotype compared to participants with the common haplotype, TT. Across RXRA, one haplotype located 39
of the coding sequence (rs748964, rs3118523), increased RCC risk 35% among individuals with the variant haplotype
compared to those with the most common haplotype. This study comprehensively evaluated genetic variation across eight
vitamin D pathway genes in relation to RCC risk. We found increased risk associated with VDR and RXRA. Replication studies
are warranted to confirm these findings.
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Introduction
Within the kidney, vitamin D is metabolized to 1,25-
dihydroxycholecalciferol (1,25(OH)2D3), the active form of
vitamin D [1]. The anti-carcinogenic properties of vitamin D
include inhibition of clonal tumor cell proliferation, induction of
immune cell differentiation and apoptosis, and decreased
angiogenesis [2,3]. Vitamin D activity is mediated through
binding of 1,25(OH)2D3 to the vitamin D receptor (VDR), which
can regulate transcription of other genes involved in cell
regulation, growth, and immunity [3–6]. VDR modulates the
expression of genes by forming a heterodimer complex with
retinoid-X-receptors (RXR)[ 7 ] .T h i sVDR-RXR complex is
directed to the vitamin D response element (VDRE)i nt h e
promoter region of several 1,25(OH)2D3 regulated genes to
initiate transcription [7,8].
Since 1,25(OH)2D3 exerts its activity through nuclear VDR,
most studies of genetic susceptibility to vitamin D related
diseases have investigated variation within the VDR gene [4,7,9–
11]. However, the concert of genes that interact with VDR is
vast; therefore, an analysis of variation in VDR and other genes
in the vitamin D pathway may provide insight into the role of
vitamin D in renal cell carcinoma (RCC) etiology. Given the
importance of vitamin D metabolism in the kidney and the lack
of studies that have evaluated the relationship between vitamin
D, the VDR gene, and RCC, we previously evaluated how three
common VDR gene polymorphisms (BsmI, FokI, TaqI) modified
RCC risk [12]. We observed reduced RCC risk among older
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e7013subjects and among subjects with a family history of cancer who
were carriers of the f alleles in the FokI single-nucleotide
polymorphism (SNP) compared with subjects with the FF
g e n o t y p e[ 1 2 ] .H o w e v e r ,g i v e nthe limited genomic coverage
of VDR in our previous candidate SNP investigation, and the
numerous genes that interact directly with VDR in the vitamin D
pathway, we expanded upon these findings to investigate
variation in candidate genes that may interact directly with
VDR to modify RCC risk and improved our analysis by
increasing regional coverage of variation across each gene to
80–90%.
Therefore, to determine whether variation in vitamin D
pathway genes modified RCC risk, we comprehensively investi-
gated the relationship between renal cancer risk and 139 tagging
SNPs across eight target genes (VDR, RXRA, RXRB, CYP24A1, GC,
STAT1, THRAP4, and TRAP5) of the vitamin D pathway among
cases and controls from Central Europe, an area with one of the
highest rates of RCC worldwide [13]. To our knowledge, this
represents one of the largest and most detailed investigations of
genetic variation within the vitamin D pathway and RCC risk
conducted to date.
Results
A description of study participants and known RCC risk factors is
provided in Table 1. All participants and only genotyped participants
showed a similar distribution of characteristics, with the exception of
sex. Cases and controls were comparable in age, but cases were more
likely to have excess body mass index (BMI) (.30 kg/m
2)a n d
hypertension, and to have a first degree relative with cancer. The
association with smoking was no longer observed after adjustment for
age, BMI, hypertension, study center, and sex [14].
Table 2 lists results for global gene-based tests of association
with case/control status using the minimum p-value permutation
(Min-P) test. VDR (p-value=0.02) and RXR-alpha (RXRA) (p-
value=0.10) genes were most strongly associated with RCC risk.
Table 1. General characteristics of participants in the CEERCC Study.
Among All Participants Among Genotyped Participant
Variables Cases Controls Cases Controls
N % N % p-value N % N % p-value
Participants 1,097 42.6 1,476 57.4 777 42.9 1,035 57.1
Sex
Males 648 59.1 952 64.5 472 60.7 648 62.6
Females 449 40.9 524 35.5 0.01 305 39.3 387 37.4 0.42
Age at Interview
,45 86 7.8 122 11.1 60 7.7 83 8.0
45–54 278 25.3 379 34.5 197 25.4 287 27.7
55–64 335 30.5 460 41.9 243 31.3 309 29.9
65–74 353 32.2 452 41.2 242 31.1 318 30.7
75+ 45 4.1 63 5.7 0.50 35 4.5 38 3.7 0.30
Mean Age (std) 59.6 yrs. (10.3) 59.3 yrs. (10.3) 59.5 yrs. (10.4) 59.0 yrs. (10.2)
Center
Romania-Bucharest 95 8.7 160 10.8 68 8.8 94 9.1
Poland-Lodz 99 8.7 198 13.4 80 8.7 189 18.3
Russia-Moscow 317 28.9 463 31.4 242 31.1 313 30.2
*Czech Republic 586 53.4 655 44.4 ,0.001 387 49.8 439 42.4 ,0.001
BMI at Interview
,25 327 29.8 532 36.0 222 28.6 375 36.3
25–29.9 476 43.4 620 42.0 330 42.5 432 41.9
30+ 294 26.8 324 22.0 ,0.001 225 29.0 225 21.8 ,0.001
Tobacco Status
Never 510 46.6 599 40.7 359 46.4 420 40.7
Ever 584 53.4 874 59.3 0.003 415 53.6 613 59.3 0.02
Hypertension
No 600 54.7 906 61.4 434 55.9 638 61.7
Yes 496 45.3 569 38.6 0.001 342 44.1 396 38.3 0.01
Familial History of Cancer Among 1
st Degree Relatives
No 733 66.8 1,074 72.8 512 65.9 745 72.0
Yes 364 33.2 402 27.2 0.001 265 34.1 290 28.0 0.01
*Brno, Olomouc, Prague, Ceske-Budejovice.
doi:10.1371/journal.pone.0007013.t001
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and minimum false discover rate (FDR) adjusted p-values for the
three SNP haplowalk sliding window for VDR and RXRA were
significantly associated with RCC risk.
Subsequently, HaploWalk based methods were used to identify
regions of interest in each gene that remained significant at an
FDR of less than 10%. Three significant VDR haplotypes (Table 3)
were identified in two regions that were associated with increased
RCC risk. The first region (Figure 1), located within intron 2,
showed subjects with the AGC (OR=1.29; 95% CI=1.10–1.52; p-
value=0.002) or GAC (OR=1.25; 95% CI=1.04–1.51; p-
value=0.02) haplotype were at a significantly increased risk
compared to patients with the most common referent haplotype,
GAT. Increased risk appeared to be driven by the T to C change at
the third loci. The second region (Figure 1), centered around
intron 4, also increased RCC risk among participants with the TC
(OR=1.31; 95% CI=1.09–1.57; p-value=0.004) haplotype
compared to participants with most common referent haplotype,
TT. The R adjusted global p-values for both of these regions were
0.04 (Table 3). Across the RXRA gene (Figure 2), a single region
located downstream, 39 of the coding sequence, was shown to be
associated with increased RCC risk among individuals with the CG
(OR=1.35; 95% CI=1.11–1.66; p-value=0.003) haplotype
compared to subjects with the most common haplotype, GA.
The R adjusted global p-value for this region was 0.03.
Results for individual analyses of these SNPs are provided in
Supplemental Table S1. Thirteen SNPs in five vitamin D pathway
genes were significantly associated with RCC risk using an additive
model (number of significant tag SNPs): VDR(5), RXRA(5),
CYP24A1(1), GC(1), and STAT1(1). No statistically significant
interactions between these SNPs and potential confounders (i.e.
BMI, age, sex, smoking status, hypertension, and a family history
of cancer) were detected (data not shown). No difference in
association between individual SNPs and RCC risk was observed
when analyses were restricted to RCC cases histologically
diagnosed with clear cell subtype (data not shown) nor when
analyses were restricted to cases with only high grades tumors
(data not shown).
Discussion
In this analysis of 139 tagging SNPs across eight vitamin D
pathway genes, we identified three regions within two genes that
were significantly associated with RCC risk. Both genes, VDR and
Table 2. Vitamin D pathway gene-based global, trend, and haplowalk minimum p-values for associations with renal cancer risk.
Target Gene Name (Alias) Target Gene Function
Chromosome
Location
Number of
Tag SNPs
Adjusted Min-P
Test
*Minimum
Adjusted
p-trend
{Haplowalk
VDR: Vitamin D 1,25
dihydroxyvitamin D3 Receptor
(NR111)
Encodes the nuclear hormone receptor
for vitamin D3 and is principally involved
in mineral metabolism through the
receptor; regulates variety of other
metabolic pathways.
12q13.11 29 0.024 0.002 0.045
RXRA: Retinoid X Receptor,
alpha (FLJ16020, FLJ16733,
MGC102720, NR2B1)
Mediates the biological effects of
retinoids; as homo- or heterodimers,
binds to the vitamin D receptor gene
and regulates transcription.
9q34.3 18 0.100 0.011 0.007
STAT1: Signal Transducer and
activator of Transcription
1, 91kDa (DKFZp686B04100,
ISGF-3, STAT91)
Phosphorylated by receptor associated
kinases; protein forms homo- or
heterodimers that translocate to the
cell nucleus where they act as transcrip-
tion activators.
2q32.2 21 0.138 0.022 0.085
RXRB: Retinoid X Receptor,
beta (DAQB-314F24.5, DAUDI6,
H-2RIIBP, MGC1831, NR2B2,
RCoR-1)
Forms homodimers with the retinoic
acid, thyroid hormone, and vitamin D
receptors, increasing binding and
transcription on response elements.
6p21.3 8 0.202 0.093 0.262
GC: Group-Specific Component
Vitamin D Binding Protein (DBP)
Binds vitamin D and its plasma metabo-
lites, transporting them to target tissues.
4q12–q13 11 0.246 0.037 0.090
THRAP5: Thyroid Hormone
Receptor Associated Protein 5
(DRIP92, MED16, TRAP95)
Selectively interacts with vitamin D
receptors, mediating the action of
vitamin D by binding and controlling
the transcription of hormone-sensitive
genes.
19p13.3 11 0.384 0.113 0.192
CYP24A1: Cytochrome P450,
Family 2, Subfamily A,
Polypeptide 1 (CP24, CYP24,
MGC126273, MGC126274, P450-
CC24)
Initiates degradation of 1,25-
dihydroxyvitamin D3; regulates levels of
vitamin D3; plays a role in calcium
homeostasis and vitamin D endocrine
system.
20q13 35 0.630 0.035 0.729
THRAP4: Thyroid Hormone
Receptor Associated Protein 4
(ARC100, CRSP100, CRSP4,
DRIP100, KIAA0130, MGC8748,
MED24, TRAP100)
Induces gene expression and selectively
interacts with vitamin D receptors
mediating the action of vitamin D by
binding and controlling the transcrip-
tion of hormone-sensitive genes.
17q21.1 6 0.936 0.580 0.927
*Adjusted minimum p-value for all tagging SNPs in a targeted gene using additive model.
{Minimum FDR adjusted p-value for 3- SNP haplowalk sliding window analysis.
*{Adjusted for age, sex, study center, and smoking status (ever, never).
doi:10.1371/journal.pone.0007013.t002
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risk, contained regions with significant associations. Across the
VDR gene, three haplotypes within two regions (intron 2 and
intron 4) were significantly associated with increased risk. Across
the RXRA gene, RCC risk was higher among those with one
particular haplotype located 39 of the coding region.
Only a handful of studies have comprehensively analyzed
genetic variation in the VDR gene in relation to cancer [15,16,17].
A case-control study of 630 incident prostate cancer patients was
conducted to comprehensively analyze genetic variation in the
VDR gene; twenty-two SNPs were genotyped to capture a high
percentage of variation in the VDR gene [17]. A two-fold increase
in prostate cancer risk was observed for two VDR loci (rs2107301
and rs2238135), which were located within introns 2 and 4,
respectively [17]. Though information is limited regarding the
association between VDR variants and RCC risk, genetic
susceptibility studies for common VDR polymorphisms, such as
BsmI, FokI, TaqI, and ApaI, have been shown to modify RCC risk
[15,16]. A recent case-control study of 135 RCC patients found
that participants with the AA genotype at the ApaI site had a
significant increase in RCC risk (OR=2.59; p-value=0.01); cases
with the AA genotype also were found to have lower survival rates
(Relative Risk=3.3; p-value=0.04) compared to cases with the Aa
or aa genotypes [16]. A two-fold increase in cancer risk was also
reported among participants with the TT genotype at the TaqI site
in a second case-control study of 102 RCC patients compared to
subjects with the Tt or tt genotype (p-value=0.001) [15].
Similarly, few previous studies of RCC risk and variation across
vitamin D pathway genes have been conducted. A small number of
polymorphisms in the VDR gene, such as poly(A),TaqI,a ndBsmI,ha ve
been speculated to result in variation of VDR expression and are
hypothesized to subsequently result in changes to circulating levels of
active vitamin D [15,18,19]. Altered VDR protein expression has
been reported in a number of tumor types including breast,
malignant gliomas, prostate, and colon cancer [20]. Moreover,
previous epidemiological studies have reported that increased binding
of vitamin D to VDR is associated with decreased RCC risk, and that
active levels of vitamin D3 in serum are significantly lower in RCC
patients compared to population controls [15,16,19]. Together these
results indicate that vitamin D levels influence RCC risk. While
results have been mixed concerning associations between variants in
the RXR gene and cancer risk [21–24], in vitro animal and human
studies have shown that elevated levels of RXRA increases the
antiproliferative effects of 1,25(OH)2D3 [25,26].
In vitro and animal studies suggest that vitamin D and its
metabolites may impede carcinogenesis by stimulating cell differ-
entiation,inhibiting cell proliferation typically characterized byG0/
G1 cell cycle arrest, apoptosis, and suppression of invassion,
angiogenesis, and metastasis [3–6]. In laboratory studies, 1,25
hydroxyvitamin D has been shown to significantly reduce tumor
growth for a variety of cancers including colon, breast, prostate and
lung [18]. The use of vitamin D or its analogs as chemopreventive
agents in humans, although limited, have shown beneficial effects.
In a clinical trial for patients with inoperable advanced hepatocel-
lular carcinoma a daily dose of 10 mg of Seocalcitol (a vitamin D
analog) for up to one year resulted in a reduction in tumor
dimension [27]. Additionally, among 37 patients with metastatic
androgen-independent prostate cancer, who were treated with a
high dose treatment of oral calcitriol/docetaxel (active form of
vitamin D/mitotic inhibitor), prostate-specific antigen reductions of
at least 50% was observed [28].
Although the magnitude of association between RCC risk and
VDR and RXRA gene variants in our study may be small, some of
these variants are relatively common in the population and therefore
may be associated with a much higher attributable risk as a whole
compared to rare high penetrance genes. Furthermore, the VDR
variantsassociated withRCC risk in thisstudy wereintronic and were
not located near intron-exon boundaries that may produce splicing
errors. These alleles seem to have no effect on the expression levels or
activity of translated VDR protein and it is hypothesized that they are
correlated with other variants with functional relevance. Synonymous
SNPs are often disregarded in many genetic susceptibility studies
based on the assumption that they do not alter amino acid sequence,
which would subsequently affect protein structure and function, nor
protein expression [29]. Yet, the list of synonymous mutations
associated with human diseases is growing [29,30]. Recent genetic
studies have shown that synonymous mutations are not random and
may play a significant role in diseaseetiology sincesynonymous SNPs
can affect protein expression and function by altering mRNA stability
[29,31,32]. Studies solely focusing on genetic variations within exonic
regions of DNA that lead to changes in protein sequence may be
simplistic and may not represent the larger picture that is evolving
between genetic variation and disease [33].
In addition to being one of the first genetic susceptibility studies
to comprehensively examine the association between VDR and
seven other vitamin D pathway genes in relation to RCC risk, an
additional strength of our study includes the use of HapMap data
to tag genes of interest using high (80–90%) genomic coverage by
tagging genomic regions, both upstream (20 kb) and downstream
(10 kb) to reduce chance of false negative findings. In this study,
we also observed high participation rates, used newly diagnosed
Table 3. Renal cancer risk and haplotypes in genes in the
vitamin D pathway.
Haplotypes
Cases
(%)
Controls
(%) OR (LCI-UCI) P-value Global
{VDR
Region 1
59-rs2254210, rs2853564, rs4760648-39
G-A-T 37.8 42.7 1.00
A-G-C 32.3 28.9 1.29 (1.10–1.52) 0.002
G-A-C 20.3 18.4 1.25 (1.04–1.51) 0.02
G-G-C 6.5 7.1 1.04 (0.78–1.38) 0.78
0.04
Region 2
59-rs2239179, rs12717991-39
T-T 37.9 41.6 1.00
C-C 37.0 37.1 1.07 (0.92–1.25) 0.36
T-C 23.6 19.7 1.31 (1.09–1.57) 0.004
0.04
{RXRA
Region 1
59-rs748964, rs3118523-39
G-A 78.9 82.8 1.00
G-G 6.5 5.9 1.11 (0.85–1.46) 0.44
C-G 14.3 11.1 1.35 (1.11–1.66) 0.003
0.03
Adjusted for age (continuous), sex, study center, and smoking habit (ever,
never).
{VDR chr12 region1: 46466932-46559981; region 2: 46545393-46544033.
{RXRA chr9 region1: 136475342-136473910.
doi:10.1371/journal.pone.0007013.t003
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biologic materials from a high proportion of subjects. The large
sample size of this study provided sufficient statistical power to
detect relatively small associations between genotypes and risk.
Analysis of genes with significant global p-values reduced the risk
of Type I errors in our study, while the use of two different
Haplotype-based methods (HaploWalk and HaploStats) reduced
the possibility of finding significant results based on chance.
Furthermore, while hospital-based case-control studies have
potential limitations due to the lack of population controls, these
studies can improve response rates for the intense collection of
biological specimens and therefore reduce the chances of bias in
Figure 1. VDR HaploWalk and Haploview analysis. Top: HaploWalk analysis identified two chromosomal regions of interest in the vitamin D
receptor (VDR) gene that were significant at an FDR of 10%. Region one included SNPs 39- rs4760648, rs2853564, rs2254210 -59; region two included
SNPs 39- rs12717991, rs2239179 -59. Bottom: Haploview analysis also identified two haplotype blocks within the same chromosomal regions of
interest.
doi:10.1371/journal.pone.0007013.g001
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did not employ a direct marker for vitamin D among these study
subjects. While there is general agreement that serum 25(OH)D
level is the best indicator of current vitamin D status, the
biochemical marker has a short half-life and would not necessarily
reflect long-term vitamin D status, particularly for case-control
studies where cases have just recently been diagnosed [35].
In conclusion, our a priori hypothesis was supported and we
observed that genetic variations in VDR and RXRA were
significantly associated with RCC risk. However, since our results
Figure 2. RXRA HaploWalk and Haploview analysis. Top: HaploWalk analysis identified a single chromosomal region of interest in the retinoid-
X-receptor-alpha (RXRA) gene that was significant at an FDR of 10%. This region included SNPs 59- rs748964, rs3118523 -39. Bottom: Haploview
analysis also identified one haplotype block within the same chromosomal region of interest.
doi:10.1371/journal.pone.0007013.g002
Vitamin D Pathway & RCC Risk
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onlybeginningtounderstandthe roleofgeneticvariationinintronic
regionsandtheireffectondisease development,additionalstudiesof
genetic variations of these two genes and RCC risk are warranted.
Materials and Methods
Study Subjects
Details of the Central and Eastern European Renal Cell
Carcinoma (CEERCC) study have been previously reported [36].
Briefly, the CEERCC study is a hospital-based case-control study
of renal cell cancer conducted between 1999 and 2003 in seven
centers in four Central and Eastern European countries (Moscow,
Russia; Bucharest, Romania; Lodz, Poland; and Prague, Olo-
mouc, Ceske-Budejovice, and Brno, Czech Republic). Each center
followed an identical protocol and was responsible for recruiting a
consecutive group of newly diagnosed cases of kidney cancer as
well as a comparable group of hospital controls. Controls in all
centers were chosen among subjects admitted as in- or out-patients
in the same hospital as the cases, with conditions unrelated to
tobacco or genitourinary disorders. No single disease made up
more than 20% of the control group. All subjects were residents of
the study areas for at least one year at the time of recruitment and
were of Caucasian descent.
Cases between 20 and 79 years of age were ascertained through
a rapid reporting system. Participating physician and other
professional staff members visiting the urology, surgery, radiology,
or pathology departments of participating hospitals regularly
identified patients admitted for kidney cancer work-up. All patients
suspected of having kidney cancer were approached for interview,
but only histologically confirmed cases were included in the final
analysis. All tumors were centrally reviewed to confirm diagnosis
and histology. The majority of renal tumors were clear cell
carcinomas (83.4%), while other subtypes included papillary (7%),
chromophobe (2.4%), oncocytoma (2.3%), oncocytic neoplasms
(0.2%), transitional cell carcinomas (1.1%), and unclassified
(3.6%). Controls were frequency-matched to cases on age (63
years), sex, and study center. A total of 1,097 confirmed incident
RCC cases and 1,476 controls were included in this study.
Genomic DNA was obtained from 987 of 1,097 (90%) of cases and
1,298 of 1,476 (88%) of controls. The response rates across study
centers among eligible subjects who were requested to participate
ranged from 90.0–98.6% for cases and 90.3–96.1% for controls.
Interview
Cases and controls were interviewed with the same question-
naire [37]. Information on demographic characteristics, medical
histories, and lifestyle factors was obtained through in-person
interviews by trained personnel using standardized lifestyle and
food frequency questionnaires. Cases were interviewed within
three months of diagnosis. Written consent for participation was
obtained from all study subjects, and ethical approval was
obtained for all study centers.
Laboratory Procedures
Genomic DNA was extracted from whole blood buffy coat using
a standard phenol chloroform method. Genotyping was conducted
with a GoldenGateH Oligo Pool All (OPA) assay by IlluminaH
(www.illumina.com) at the National Cancer Institute’s (NCI’s)
Core Genotyping Facility (CGF) where lab staff was blinded to
cases/control status. Suitable quantity and quality of genomic
DNA was obtained from a subset of 777 (70.8%) RCC cases and
1,035 (70.1%) controls, due to strict quality and quantity criteria
for analysis using the IlluminaH OPA panel.
A literature review of vitamin D associated genes helped identify
eight candidate genes (VDR, RXRA, RXRB, CYP24A1, GC, STAT1,
THRAP4 and THRAP5) that were ultimately selected for their
involvement in vitamin D metabolism, transport, binding, function
and/or expression, which may affect the mechanisms through
which vitamin D may influence cancer risk. Since it is well known
that VDR elicits a transcriptional response by forming a
heterodimer complex with the retinoid-X-receptor, in this study
both VDR and RXR were the primary genes suspected a priori to
modify renal cancer risk. The group specific component (GC)
vitamin D binding protein was selected for its involvement as the
major carrier of vitamin D in plasma [38]. Cytochrome P450,
family 24, subfamily A, polypeptide 1 (CYP24A1) was selected for
its involvement in degrading and regulating 1,25(OH)2D3 levels
[39,40]. Lastly, the signal transducer and activator of transcription
1( STAT1) and the thyroid hormone receptor associated protein 4
and 5 (THRAP4 and THRAP5) genes were selected since studies
indicate that these genes may induce or suppress transcription by
interacting with the VDR-RXR complex [41,42].
Tag SNPs were selected to provide 80–90% genomic coverage
across the genomic regions of interest. To ensure thorough
coverage of the targeted region, additional coverage of regions
both upstream (20 kb) of the start of transcription and downstream
(10 kb) of the last exon using HapMap CEU data (http://www.
hapmap.org) among SNPs with minor allele frequencies of at least
5% and an r
2$80% were selected. Additionally, non-synonymous
SNPs or those correlated with polymorphisms with potential
functional significance were included in analysis. In total, 139
SNPs in eight vitamin D-related pathway target genes were
selected for analysis. The total length of sequence analyzed across
all genes was 495,664 bases (VDR: 37,421 bases, RXRA: 144,022
bases, RXRB: 36,257 bases, CYP24A1: 50,537 bases, GC: 72,479
bases, STAT1: 75,061 bases, THRAP4: 39,862 bases, and
THRAP5: 40,025 bases). Replicate quality control samples (5%
samples) were interspersed among genotyping plates. The
genotyping failure rate for the selected SNPs was 4.8% (7/146).
The concordance rate between duplicate DNA samples ranged
from 93–100% and completion rates ranged from 98–100%. The
genotype frequencies among controls did not differ from the
expected Hardy-Weinberg equilibrium proportions (p.0.05). All
SNPs and assay information are reported in NCI’s SNP500Cancer
Database (http://snp500cancer.nci.nih.gov) [43].
Statistical Analysis
The distributions of selected characteristics and known RCC
risk factors (sex, age, smoking habits, hypertension, BMI, family
history of cancer, and country of residence) were compared
between genotyped cases and controls using the Chi-square test.
These characteristics were further evaluated to determine if
associations between SNPs and RCC were modified; however, no
significant interactions were observed between cancer risk, RCC
risk factors, and SNPs (data not shown).
The associations between individual SNPs and RCC risk were
estimated by calculating odds ratios (ORs) and 95% confidence
intervals (95% CI) using unconditional logistic regression.
Interactions were tested comparing regression models with and
without interaction terms using a likelihood ratio test (LRT). All
regression models were adjusted for age (continuous), sex, study
center, and smoking habit (ever, never). Additional risk factors (i.e.
hypertension, BMI, and family history of cancer) were also
considered, however, these variables did not affect risk estimates
by at least 10%. To avoid redundant analyses, only one SNP was
evaluated when high correlations were observed between two
SNPs (r
2.0.85). Of the 139 SNPs genotyped, two pairs of SNPs in
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2=0.95 for
rs1544410 (BsmI) and rs731236 (TaqI); r
2=0.89 for rs2248098 and
rs2239185) and therefore only one SNP was used per pair
(rs1544410 (BsmI) and rs2248098).
Since the most common form of renal cell carcinoma is of clear
cell type, associations between individual SNPs and RCC risk were
also evaluated among cases histologically diagnosed with this
subtype of renal cancer. However restricting cases to those with
clear cell type did not affect risk estimates by at least 10% (data not
shown). Similarly, analyses restricted to cases with only high grades
tumors did not affect risk estimates (data not shown).
Risk estimates were calculated for the heterozygous and
homozygous variant genotypes relative to the common homozy-
gous genotype assuming an additive model. When the frequency
of the homozygous variant allele was less than 5% among controls,
a dominant model was used to determine risk estimates for the
presence and absence of the variant allele. Associations between
SNP variants and RCC were assessed using an additive model (i.e.
linear test of trend for the number of copies of the variant allele (0,
1, 2)) or a dominant model (i.e. Wald chi-square test for the
presence or absence of the variant allele (0, 1)). To assess global
significance of association with genes, a minimum p-value
permutation (Min-P) test was used for analysis because it corrects
for multiple testing while also accounting for correlations between
SNPs within a gene [44]. Genes that had a significant Min-P test at
a cut-off level of 10% were selected for further analysis. Analysis
for genes that did not meet this criterion is available in
Supplemental Figure S1, S2, S3, S4, S5, S6.
HaploWalk, a haplotype-based sliding window analytic method,
was used to evaluate candidate genes with N=K SNPs. The
HaploWalk procedure considered a three SNP window for each
SNP from SNP 2 through SNP K-1. For each window, haplotype
frequencies in cases and controls were reconstructed using the EM
algorithm [45], and a Wald test was used to screen for association
with case-control status [44]. In the initial screening phase, no
adjustment was made for potential confounders. The Wald test used
a threshold value of 5%, such that haplotypes in cases and controls
that had an estimated frequency below the threshold in controls
were pooled into an ‘other’ rare haplotype category for testing. To
account for multiple testing acrossthe K SNPs, the K-2 p-values (one
for each window) were adjusted for multiple comparisons using the
False Discovery Rate (FDR)-controlling procedure of Benjamini
and Hochberg [46]. Haplotype windows with an FDR-adjusted
value of ,10% were promoted to the second stage.
In stage two, haplotype blocks identified with HaploWalk were
analyzed in relation to RCC risk using Haplostats (R version 2.4.0;
http://www.r-project.org) [47], adjusted for age, sex, study center,
and smoking habit. Additionally, we used standard methods to
identify haplotypes using the Haploview program version 3.32
[48]. Linkage disequilibrium between markers was assessed by
calculating pairwise Lewontin’s D’ and r
2 using Haploview among
population controls [48]. Heterogeneity of genotype frequencies
among countries was evaluated by using the likelihood ratio test to
compare the fit of models with and without interaction terms, but
we did not find evidence of heterogeneity across populations. No
evidence of population stratification was apparent from a principal
components analysis of a genome wide association study
conducted in this population [49], and the likelihood of this is
small among European populations [50]. Associations between
common haplotypes (.5% frequency) and RCC risk were
evaluated by computing ORs and 95% CIs using the most
common haplotype category for comparison. All analyses were
conducted in STATA 9.0 unless otherwise specified (STATA
Corporation, College Station, TX).
Supporting Information
Table S1 SNP-based analysis main effects for vitamin D
pathway genes
Found at: doi:10.1371/journal.pone.0007013.s001 (1.73 MB
DOC)
Figure S1 RXRB HaploWalk and Haploview analysis. Top:
HaploWalk analysis identified no chromosomal regions of interest
in the retinoid-X-receptor-beta (RXRB) gene that were significant
at an FDR of 10%. The Min-P test for this gene was not
statistically significant (p-value=0.20). Bottom: Haploview analy-
sis identified two haplotype blocks; none were associated with
RCC risk when analyzed in Haplostats.
Found at: doi:10.1371/journal.pone.0007013.s002 (0.24 MB TIF)
Figure S2 CYP24A1 HaploWalk and Haploview analysis. Top:
HaploWalk analysis identified no chromosomal regions of interest
in the cytochrome P450, family 24, subfamily A, polypeptide 1
(CYP24A1) gene that were significant at an FDR of 10%. The
Min-P test for this gene was not statistically significant (p-
value=0.63). Bottom: Haploview analysis identified several
haplotype blocks; none were associated with RCC risk when
analyzed in Haplostats.
Found at: doi:10.1371/journal.pone.0007013.s003 (0.76 MB TIF)
Figure S3 GC HaploWalk and Haploview analysis. Top:
HaploWalk analysis identified no chromosomal regions of interest
in the group specific component (GC) vitamin D binding protein
that were significant at an FDR of 10%. The Min-P test for this
gene was not statistically significant (p-value=0.25). Bottom:
Haploview analysis identified one haplotype block which was not
associated with RCC risk when analyzed in Haplostats.
Found at: doi:10.1371/journal.pone.0007013.s004 (2.86 MB TIF)
Figure S4 STAT1 HaploWalk and Haploview analysis. Top:
HaploWalk analysis identified a single chromosomal region of
interest in the signal transducer and activator of transcription 1
(STAT1) gene that was significant at an FDR of 10%. This region
included SNPs 39- rs3755821, rs6751855, rs1467199, rs13029532
-59. The Min-P test for this gene was not statistically significant (p-
value=0.14). Bottom: Haploview analysis also identified one
haplotype block within the same chromosomal region of interest.
Haplostats analysis adjusted for age, sex, study center, and
smoking habit showed that subjects with the CGGA haplotype
had an increased risk of RCC (OR=1.21; 95% CI=1.01–1.45; p-
value=0.04) compared to subjects with the referent haplotype,
GACA.
Found at: doi:10.1371/journal.pone.0007013.s005 (1.76 MB TIF)
Figure S5 THRAP4 HaploWalk and Haploview analysis. Top:
HaploWalk analysis identified no chromosomal regions of interest
in the thyroid hormone receptor associated protein 4 (THRAP4)
gene that were significant at an FDR of 10%. The Min-P test for
this gene was not statistically significant (p-value=0.94). Bottom:
Haploview analysis identified one haplotype block which was not
associated with RCC risk when analyzed in Haplostats.
Found at: doi:10.1371/journal.pone.0007013.s006 (1.42 MB TIF)
Figure S6 THRAP5 HaploWalk and Haploview analysis. Top:
HaploWalk analysis identified no chromosomal regions of interest
in the thyroid hormone receptor associated protein 5 (THRAP5)
gene that were significant at an FDR of 10%. The Min-P test for
this gene was not statistically significant (p-value=0.38). Bottom:
Haploview analysis identified several haplotype blocks; none were
associated with RCC risk when analyzed in Haplostats.
Found at: doi:10.1371/journal.pone.0007013.s007 (0.64 MB TIF)
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